BG Negev licenses Parkinson’s drug platform

"The success of this project should improve Parkinson’s patients’ lives," says Prof. Eliahu Heldman.

By GLOBES CORRESPONDENT
April 11, 2012 22:17
1 minute read.
Scientists in a laboratory

DNA laboratory 311. (photo credit: iStockphoto)

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

BGN Technologies, the technology transfer company for Ben-Gurion University of the Negev, has signed a licensing agreement for its V-Smart drug delivery technology with Lauren Sciences LLC, a privately held biotechnology company in New York.

Lauren Sciences will develop the technology as a platform for treating central nervous system diseases, including Parkinson’s, Alzheimer’s, Amyotrophic Lateral Sclerosis, and brain malignancies.

Be the first to know - Join our Facebook page.


The V-Smart technology pinpoints where the drug will be released in the brain, increasing effectiveness and reducing adverse effects. VSmart technology is based on nanovesicles made of proprietary building blocks that provide high stability, large encapsulation capacity, targeting to specific cells and tissues, a controlled release mechanism, and passage through biological barriers, including the blood brain barrier (BBB).

The drug delivery platform was developed by BGU researchers Dr. Sarina Grinberg of the Department of Chemistry, Dr. Charles Linder of the Department of Biotechnology and Prof. Eliahu Heldman of the Department of Clinical Biochemistry, who also serves as Lauren Science’s chief scientific officer. Lauren Sciences will continue to conduct development activities at BGU.

“Our pre-clinical studies demonstrate that novel, nano-sized V-Smart vesicles encapsulate small molecules, peptides, proteins and nucleic acids, cross the BBB and release their encapsulated contents in the brain,” said Heldman. “Our goal is to target, protect and restore dopaminergic neurons [nerve cells] in the brain that deteriorate during the course of Parkinson’s disease. The success of this project should improve Parkinson’s patients’ lives.”

The BBB is permeable for small molecules, however an active drug delivery transport system is required for other substances. There is currently an unmet need and a great medical challenge for a safe, effective and reliable drug delivery transport system to deliver viable chemotherapeutic agents to the brain of patients with brain cancer or other CNS related clinical states.

The V-Smart platform is protected by several worldwide patents filed by BGN Technologies. Lauren Sciences was recently awarded a grant from the Michael J. Fox Foundation to develop a V-Smart therapeutic for Parkinson’s disease.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS